Analytical Data
-
基因名
HLA-A*02:01&B2M&LMP2(CLGGLLTMV) Tetramer
- Application
-
别名
MHC; RMF; LMP2; LMP-2; Macropain chain 7; Proteasome chain 7; PSMB9; RING12
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A140T913 (G25-T305)&P61769
-
表达区间
A0A140T913 (G25-T305)&P61769 (I21-M119)&CLGGLLTMV
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of Chimeric HLA-A*02:01(mα3)&B2M&LMP2(CLGGLLTMV) monomer recombinant protein is rooted in the quest for effective cancer immunotherapy. The human leukocyte antigen (HLA) system plays a crucial role in the immune response, particularly in presenting tumor-associated peptides to T cells. HLA-A*02:01 is one of the most common class I antigens in the human population, making it a key target for therapeutic strategies. The incorporation of a specific peptide derived from LMP2 (CLGGLLTMV), which is recognized by T cells, enhances the potential of this chimeric protein to elicit a robust immune response against tumors. The monomeric form enables a more straightforward analysis of molecular interactions and a better understanding of T cell receptor binding dynamics. Moreover, the use of recombinant technologies allows for efficient production and characterization of this protein, paving the way for potential applications in vaccine development and adoptive T cell therapies. Overall, this research aims to elucidate the mechanisms through which these chimeric proteins can improve anti-tumor immunity and contribute to the advancement of personalized medicine in cancer treatment.
